Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma

Research output: Contribution to journalArticle

Abstract

Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.

Original languageEnglish (US)
Article numberbcr-2017-222064
JournalBMJ Case Reports
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Autoimmune Hemolytic Anemia
Lymphoma, Large B-Cell, Diffuse
Complement Inactivating Agents
Therapeutics
Lymphoproliferative Disorders
Autoantibodies
Non-Hodgkin's Lymphoma
Autoimmune Diseases
Anemia
Erythrocytes
cold agglutinins
Drug Therapy
Infection
Neoplasms

Keywords

  • haematology (drugs and medicines)
  • malignant and benign haematology
  • malignant disease and immunosuppression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma. / Wongsaengsak, Sariya; Czader, Magdalena; Suvannasankha, Attaya.

In: BMJ Case Reports, Vol. 2018, bcr-2017-222064, 01.01.2018.

Research output: Contribution to journalArticle

@article{d010149bf37641dba6fcf59a93888773,
title = "Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma",
abstract = "Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.",
keywords = "haematology (drugs and medicines), malignant and benign haematology, malignant disease and immunosuppression",
author = "Sariya Wongsaengsak and Magdalena Czader and Attaya Suvannasankha",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/bcr-2017-222064",
language = "English (US)",
volume = "2018",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma

AU - Wongsaengsak, Sariya

AU - Czader, Magdalena

AU - Suvannasankha, Attaya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.

AB - Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.

KW - haematology (drugs and medicines)

KW - malignant and benign haematology

KW - malignant disease and immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=85049954287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049954287&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-222064

DO - 10.1136/bcr-2017-222064

M3 - Article

VL - 2018

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - bcr-2017-222064

ER -